Early bactericidal activity of new drug regimens for tuberculosis

The Lancet

Volumn 381, Issue 9861, 2013, Pages 111-

  Udwadia, Zarir ^a  

^a P D HINDUJA NATIONAL HOSPITAL   (India)

Author keywords

[No Author keywords available]

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; BEDAQUILINE; ISONIAZID; MOXIFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; BACTERICIDAL ACTIVITY; HUMAN; LETTER; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; SPUTUM; TUBERCULOSIS; FEMALE; LUNG TUBERCULOSIS; MALE; NOTE;

ANTITUBERCULAR AGENTS; FEMALE; HUMANS; MALE; TUBERCULOSIS, PULMONARY;

EID: 84872074257     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)60040-9     Document Type: Letter

References (4)

1. Diacon AH, Dawson R, von Groote-Bidlingmaier F, et al. 14 day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifl oxacin combinations: a randomised trial. Lancet 2012; 380: 986-93.
2. Udwadia ZF. MDR, XDR, TDR tuberculosis: ominous progression. Thorax 2012; 67: 286-88.
3. Udwadia ZF, Amale RA, Abjani KK, et al. Totally drug-resistant tuberculosis in India. Clin Infect Dis 2012; 54: 579-81.
4. Agarwal D, Udwadia ZF, Rodrigues C, et al. Increasing incidence of fl uoroquinolone resistant Mycobacterial tuberculosis in Mumbai, India. Int J Tuberc Lung Dis 2009; 13: 79-83.